Form 8-K - Current report:
SEC Accession No. 0001104659-25-004967
Filing Date
2025-01-22
Accepted
2025-01-21 19:21:34
Documents
15
Period of Report
2025-01-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm253966d1_8k.htm   iXBRL 8-K 28475
2 EXHIBIT 99.1 tm253966d1_ex99-1.htm EX-99.1 13073
6 GRAPHIC tm253966d1_ex99-1img001.jpg GRAPHIC 3236
  Complete submission text file 0001104659-25-004967.txt   227402

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avbp-20250121.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avbp-20250121_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avbp-20250121_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm253966d1_8k_htm.xml XML 3815
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 25543611
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)